Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Osteosarcoma × fluzoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Breast Neoplasms 4 Sarcoma 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Sarcoma, Ewing 1 Recurrence 1 Osteosarcoma 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Metastatic Castration Resistant Prostate Cancer 1 Kenny-Caffey syndrome, Type 1 1 Her-2 Negative Breast Cancer 1 Female Breast Cancer Patients 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1 Advanced Solid Tumors 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Ifosfamide 13 Doxorubicin 10 Methotrexate 9 Filgrastim 8 Cisplatin 8 Cyclophosphamide 7 Magnetic Resonance Spectroscopy 6 Etoposide 6 X-Rays 5 Specimen Handling 5 Sirolimus 5 Phantoms, Imaging 5 Neoadjuvant Therapy 5 Leucovorin 5 Gemcitabine 5 Nuclear Medicine Department, Hospital 4 Nivolumab 4 Drug Therapy 4 Docetaxel 4 Biopsy 4 regorafenib 3 palbociclib 3 olaparib 3 mifamurtide 3 cixutumumab 3 camrelizumab 3 cabozantinib 3 apatinib 3 Vincristine 3 Topotecan 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06074692 2023-10-31

PRIMA

Ruijin Hospital

Phase 2 Recruiting

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡